The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published online Jan. 21 in JAMA Network ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Dr Reddy’s shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).

Semaglutide is a powerful aid for managing weight and Type 2 diabetes, but it’s not a free pass to stick with old habits—or skip taking action altogether. If you’ve been struggling with weight loss, ...

A viral video from a northeast Indianapolis gas station shows a man pointing a handgun in a woman's face and shoving her up against a car while threatening her. Police have since arrested the man on ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

The House of Representatives passed a bill on Thursday to mandate doctors perform lifesaving care for babies born alive after abortion attempts. The search for two teens missing on Oahu's North Shore ...

Just because Wall Street likes a stock doesn't mean it's a great pick. In some cases, they're so optimistic that their price ...